Healthcare is undergoing a quiet but significant shift—moving away from episodic treatment models and towards continuous, data-driven optimisation of human performance.
At the centre of this evolution is The Brain & Performance Centre – a DP World company, which positions itself at the intersection of clinical care, neuroscience, and longevity science.
In this interview, Dr Craig Cook, Chief Executive Officer, discusses the emerging field of “performance medicine,” the growing role of biomarker-led healthcare, and why the future of medicine may be defined less by treating illness—and more by continuously improving how people function in daily life.
1. Your offering sits beyond traditional healthcare. How do you define “Performance Medicine,” and where does it sit between clinical care, wellness, and longevity science?
Performance medicine exists because the traditional model leaves a gap.
Healthcare is largely built to respond once something has gone wrong. Wellness tends to focus on general lifestyle improvements. Longevity science looks at extending lifespan. All of these have value, but none of them are designed around one central question: how well is someone actually functioning today, and how much better could they be?
That is where performance medicine sits.
It is a model built around measuring function before failure, identifying where the brain and body are underperforming, and applying targeted, clinically grounded interventions to improve that. It is not about treating disease alone, and it is not about general wellbeing in isolation. It is about optimisation that is measurable, repeatable, and sustained over time.
This perspective is not just clinical; it is also personal. Through my experience as a parent supporting a child through neurological care, I saw first-hand how fragmented the system can be, with assessments, therapies, and interventions happening in isolation, without a clear, measurable path connecting them. That gap between intervention and outcome is what performance medicine is designed to address.
At The Brain & Performance Centre, this translates into a structured approach: deep assessment, personalised intervention, and continuous tracking. The goal is not just to stabilise health, but to actively improve how people think, feel, and perform in their daily lives.
2. Are you primarily targeting patients, or high-performing individuals looking to optimise cognition and physical output? How does that distinction shape your model?
In practice, that distinction is far less meaningful than it sounds.
We see individuals across a spectrum. On one end, there are people recovering from neurological events such as stroke or concussion. On the other, there are high-performing individuals who are not unwell but recognise that their cognitive or physical output is not where it could be.
What connects them is not their label, but their level of function.
Both groups are asking the same underlying question: how well am I operating, and how much better could I be? The difference is simply where they are starting from.
In reality, individuals often move along this spectrum over time. Someone may begin in a recovery phase and later shift toward optimisation and long-term performance. That journey is rarely linear, and it is often where traditional systems fall short, because care is delivered in isolated moments rather than as part of a continuous process.
That understanding is reinforced by seeing how individuals and families experience these transitions in real life. The challenge is rarely access to individual interventions, it is the lack of structure, continuity, and measurable progress across the entire journey.
Our model is built around that idea. Every individual goes through a comprehensive, data-led assessment to establish a baseline. From there, we design a programme that targets specific gaps, whether that is recovery, optimisation, or long-term resilience.
3. A structured 12-week, data-intensive programme suggests a premium, high-touch model. How do you think about scalability versus exclusivity in this space?
It is a high-touch model by necessity, not by design preference.
When you are dealing with complex systems like the brain and body, and you are aiming for measurable change, depth matters. The 12-week structure allows us to assess properly, intervene with precision, and track outcomes over time. Without that level of engagement, results become inconsistent.
The challenge is that this kind of model does not scale in the same way as traditional healthcare or wellness services.
For us, scalability comes from standardising the science and the methodology, not the experience itself. The way we assess, the protocols we use, and how we measure outcomes can be replicated. The delivery, however, has to remain personalised.
There is also a practical reality: not every model should be scaled indiscriminately. If you dilute the level of care to reach more people, you risk undermining the very outcomes that define the model.
Over time, there are ways to expand access, through education, partnerships, and tiered engagement, but the core principle remains the same. Scale only works if the results hold.
4. Your programme is built around assessments, biomarker tracking, and longitudinal monitoring. How central is data to your value proposition versus the therapy itself?
Data is what makes the therapy precise.
In many parts of healthcare and wellness, interventions are applied without a clear baseline or a reliable way to measure change. That creates variability in outcomes and limits accountability.
We approach this differently. Every programme starts with a detailed assessment of cognitive, physical, and metabolic function. That gives us an objective starting point. From there, data guides every decision, from how the programme is designed to how it is adjusted over time.
A typical case might involve identifying specific deficits in cognitive processing speed or metabolic efficiency, applying targeted interventions such as hyperbaric oxygen therapy, structured physical conditioning, and nutritional adjustments, and then tracking how those markers evolve over the course of the programme.
That said, data on its own has no value. The impact comes from how it is interpreted and translated into action. The combination of data and intervention is what drives outcomes. Separating the two misses the point.
5. As you collect increasingly granular health and cognitive data, how do you translate that into actionable insights that meaningfully improve outcomes?
The focus is not on collecting more data. It is on using the right data.
One of the challenges in this space is that it is easy to overwhelm both clinicians and individuals with metrics that do not lead to meaningful decisions. Our role is to filter that complexity and focus on what actually drives change.
We identify the markers that are directly linked to cognitive function, physical performance, and overall resilience. From there, we translate those into specific actions, whether that is adjusting treatment protocols, refining nutrition, or modifying cognitive and physical training.
The longitudinal element is critical. By tracking how individuals respond over time, we can refine the programme continuously rather than relying on static plans. That is where real progress happens.
Ultimately, success comes down to clarity. Individuals do not need more information; they need clear direction on what to do next. Our job is to bridge that gap.
6. Do you see a future where individuals have something like a “personal health operating system,” and is your platform moving in that direction?
That is where the industry is heading, but more importantly, it is where it needs to go.
Today, most people experience healthcare as a series of disconnected interactions. Data sits in different systems, assessments are done in isolation, and there is very little continuity in how decisions are made.
A personal health operating system is essentially about integration. It is about having a continuous, structured view of how the brain and body are functioning, and using that to guide decisions over time.
We are already applying elements of that approach. Our programmes bring together assessment, intervention, and monitoring into a single framework. The next step is extending that beyond defined programme periods into something more continuous.
The objective is not more data, it is better decision-making. A system that provides clarity on what is happening, what it means, and what to do next.
7. Hyperbaric oxygen therapy has been used clinically for years but is now gaining traction in performance and longevity circles. Where is the strongest clinical evidence today, and where is more validation still needed?
Hyperbaric oxygen therapy has a well-established clinical foundation, particularly in recognised medical indications.
What is evolving is how it is being applied within performance and longevity contexts.
At The Brain & Performance Centre, we do not rely solely on external literature. We place significant emphasis on our own outcome tracking and clinical experience. Through that, we have seen measurable improvements in cognitive function, recovery, and broader aspects of physical performance when the therapy is applied within a structured, data-led programme.
That said, this is still an evolving field. While the evidence base is growing, particularly around neurological and recovery applications, there is a need for continued large-scale validation, especially in broader performance populations and over longer timeframes.
Our approach reflects that balance. We apply the therapy where there is strong clinical rationale, measure outcomes rigorously, and continue contributing to the evidence base through our own work.
8. Many wellness providers now offer HBOT. What differentiates your protocol from standard applications, and how do you ensure clinical rigor?
The key difference is that we do not treat hyperbaric oxygen therapy as a standalone service.
In many settings, it is delivered in isolation, often with standardised protocols and limited personalisation. That approach inherently limits its effectiveness.
Our model starts with a detailed understanding of how the individual is functioning. HBOT is then integrated into a broader programme that includes physical conditioning, cognitive training, and nutritional strategy.
The protocol itself is also highly controlled. Pressure, duration, and frequency are tailored to the individual and adjusted over time based on measurable progress.
Clinical rigour comes from that combination of personalisation and accountability. We establish baselines, track changes continuously, and refine the intervention based on objective outcomes.
Ultimately, it is not the therapy itself that differentiates the model. It is how precisely and how consistently it is applied.
9. What makes the United Arab Emirates a suitable environment for a model like this? Are you seeing a shift in how healthcare is consumed here?
The UAE is an interesting market because it combines opportunity with real structural challenges.
On one hand, there is a highly engaged, performance-driven population that is open to new healthcare models. There is also strong infrastructure and a willingness to adopt innovation early.
On the other hand, the system is still largely built around episodic care and insurance-driven interactions. Most advanced, performance-focused interventions are not directly covered, which creates friction for individuals who need to invest upfront and navigate reimbursement processes.
That dynamic is important. It means that engagement in this type of model requires a higher level of commitment, both financially and behaviourally.
What we are seeing, however, is a shift. More individuals are moving beyond purely reactive care and looking for ways to improve how they function over time. They are becoming more outcome-focused and more willing to invest in long-term health.
So while the UAE presents challenges, it is also one of the few markets where the mindset, demand, and infrastructure are evolving in a way that supports this model.
10. Do you see the UAE as a testbed for future healthcare models that could be scaled globally, particularly in preventive and performance-focused care?
Yes, and that is largely due to the speed at which the market can adapt.
The UAE allows for relatively rapid testing and refinement of new models. You have access to a diverse population, advanced infrastructure, and a regulatory environment that is open to innovation.
For performance and preventive healthcare, that is critical. These models require iteration. You need to test approaches, measure outcomes, and refine continuously.
What works here can then be adapted to other markets. The core principles, data-led assessment, personalised intervention, and continuous monitoring, are universal. The delivery model is what changes.
In that sense, the UAE plays a valuable role in shaping what scalable, future-facing healthcare models can look like.
11. Looking ahead, do you believe healthcare systems will increasingly move toward continuous optimisation rather than episodic treatment? And what does that mean for traditional providers?
There is a clear shift in that direction, driven by both technology and changing expectations.
People no longer want to engage with healthcare only when something goes wrong. They want to understand how they are functioning day to day, and how they can improve that over time.
Continuous optimisation addresses that need, but it also requires a different approach. It is not just about adding more services, it is about building systems that support ongoing engagement, measurement, and adjustment.
For traditional providers, this is an expansion rather than a replacement. Acute care will always be essential. The opportunity is in building layers around it that support long-term outcomes.
The challenge is that this requires a shift in mindset. Moving from episodic care to continuous optimisation means focusing on sustained outcomes, not isolated interventions.
Not every provider is structured for that shift, but those that adapt will be better positioned for where the industry is heading.
12. Ultimately, how should success be measured in this new model: clinical outcomes, quality of life, or even cognitive and professional performance?
It has to be measured across all three.
Clinical outcomes provide the foundation. They ensure that what we are doing is safe, effective, and grounded in science.
Quality of life reflects how those changes are experienced day to day, energy levels, clarity of thought, resilience.
Performance takes it one step further. It shows how those improvements translate into real-world capability, whether that is cognitive output, physical endurance, or professional effectiveness.
The value of this model is in connecting those dimensions. If clinical markers improve but there is no change in how someone functions, the model has failed. If performance improves but it is not sustainable, it is not meaningful.
Success is defined by measurable, sustained improvement across all three, and the ability to maintain that over time.
